Department of Cardiology, Carmel Medical Center, Haifa, Israel.
Department of Cardiology, Carmel Medical Center, Haifa, Israel.
Heart Lung Circ. 2022 Mar;31(3):390-394. doi: 10.1016/j.hlc.2021.09.005. Epub 2021 Oct 1.
Transcatheter aortic valve replacement (TAVR) is preferably performed as a completely percutaneous procedure via transfemoral access. Suture-mediated vascular closure devices are deployed prior to sheath insertion (pre-closure). Inability to perform pre-closure may necessitate surgical vascular repair of the femoral artery. Patients at increased risk of vascular surgery complications may benefit from a percutaneous method for achieving access site haemostasis. Stent graft implantation is commonly used for treating access site injury following TAVR. This study assessed the feasibility of a strategy of planned stent graft implantation within the femoral artery for achieving access site haemostasis in patients undergoing transfemoral TAVR and in whom vascular pre-closure was not possible.
A prospective institutional TAVR registry was retrospectively analysed and a cohort of patients were identified who were selected for transfemoral valve delivery and in whom pre-closure failed and access site haemostasis was achieved by stent graft implantation.
This strategy was used for achieving access site haemostasis in 11 patients (1.5% of 744 patients undergoing transfemoral TAVR). These patients were considered to be at increased risk of vascular surgery complications due to advanced age, frailty, comorbidities, or immobility. Stent graft implantation achieved access site haemostasis in all patients. During follow-up, 30-day mortality was zero, 1-year mortality was 27%, and none of the patients required additional vascular interventions.
The preliminary data suggest that planned stent graft implantation within the femoral artery may achieve access site haemostasis and enable a totally percutaneous TAVR procedure, despite failure to perform pre-closure with a suture-based vascular closure device.
经导管主动脉瓣置换术(TAVR)优选通过经股入路进行完全经皮操作。在鞘管插入(预闭)之前部署缝合介导的血管闭合装置。无法进行预闭可能需要对股动脉进行外科血管修复。有发生血管手术并发症风险增加的患者可能受益于用于实现入路部位止血的经皮方法。支架移植物植入术通常用于治疗 TAVR 后入路部位损伤。本研究评估了在经股 TAVR 过程中,对于那些无法进行预闭且需要血管闭合的患者,在股动脉内计划进行支架移植物植入以实现入路部位止血的策略的可行性。
回顾性分析了一个前瞻性的机构 TAVR 登记处,并确定了一组患者,他们被选择进行经股瓣膜输送,并且在预闭失败的情况下,通过支架移植物植入术实现了入路部位止血。
该策略用于 11 名患者(744 名经股 TAVR 患者中的 1.5%)实现入路部位止血。这些患者由于年龄较大、体弱、合并症或不能活动而被认为有发生血管手术并发症的风险增加。支架移植物植入术在所有患者中实现了入路部位止血。在随访期间,30 天死亡率为零,1 年死亡率为 27%,且无患者需要额外的血管介入治疗。
初步数据表明,尽管使用缝合介导的血管闭合装置进行预闭失败,但在股动脉内计划进行支架移植物植入术可能实现入路部位止血并使 TAVR 完全经皮进行。